8-K: Aytu BioPharma Secures Expanded and Extended Lending Agreement to Fuel EXXUA Launch

Aytu BioPharma has successfully expanded and extended its lending agreement with Eclipse Business Capital LLC, increasing its term loan to $13.0 million and adding a $1.5 million incremental revolving advance, providing crucial working capital flexibility ahead of the EXXUA commercial launch.

Summary

• Aytu BioPharma, Inc. (Aytu) entered into Amendment No. 6 to its Loan and Security Agreement with Eclipse Business Capital LLC on June 20, 2025.
• The amendment extends the maturity date for both the Eclipse Term Loan and the Eclipse Revolving Loan to June 12, 2029, from the previous June 12, 2028.
• The outstanding principal amount of the Eclipse Term Loan was increased to $13.0 million on the closing date of the amendment. This includes a new Amendment No. 6 Term Loan of $1,857,144, added to the existing Initial Term Loan balance of $11,142,856.
• The revolving credit facility was increased by a $1.5 million incremental advance, with an interest rate of SOFR plus 5.50%.
• Repayment of the $1.5 million incremental advance will commence on August 1, 2025, with monthly payments of $125,000 until fully repaid.
• The borrowing base supporting the Eclipse Revolving Loan was revised to permit concentration limits on certain independent pharmacy distributors of 25%.
• The Company paid a Revolver Closing Fee of $40,000 and a Term Loan Closing Fee of $30,000.
• The funds are intended to provide working capital flexibility for the commercial launch of EXXUA, a newly approved antidepressant.

Sentiment

Score: 7

Explanation: The document reflects a positive development for Aytu BioPharma, securing additional financial flexibility and extending debt maturities to support the commercial launch of a key product (EXXUA) in a large market. While debt incurs costs and covenants, the overall tone and strategic alignment suggest a proactive and beneficial financial move.

Positives

• Extended maturity date for both term loan and revolving credit facility to June 12, 2029, providing longer-term financial stability.
• Increased term loan principal to $13.0 million, enhancing capital availability.
• Expanded revolving credit facility by $1.5 million, offering additional working capital flexibility.
• Secured financing specifically to support the commercial launch of EXXUA, a first-in-class antidepressant, indicating confidence in the product's potential.
• Management expresses gratification for the support from equity shareholders and lending partners, highlighting the perceived growth catalyst of EXXUA.

Negatives

• The incremental advance carries an interest rate of SOFR plus 5.50%, which is higher than the general Revolving Loan rate of SOFR plus 4.50%, indicating a higher cost for this specific capital.
• The company incurred closing fees of $40,000 for the Revolver and $30,000 for the Term Loan.
• Early payment/termination premiums apply if the loans are repaid or commitments terminated prior to the scheduled maturity, ranging from 0.5% to 3.0% depending on the timing and type of loan.

Risks

• Financial Covenants: The company must maintain a Fixed Charge Coverage Ratio greater than 1.1:1.0 and Excess Availability greater than $2,500,000 for certain actions (e.g., Permitted Acquisitions, cash dividends). Failure to meet these could trigger an Event of Default.
• Capital Expenditure Limitation: Capital expenditures are limited to $3,000,000 per fiscal year, which could restrict future growth or operational needs if not managed carefully.
• Early Payment/Termination Premiums: Significant premiums (up to 3.0%) are applicable if the loans are repaid or commitments terminated early, potentially hindering future refinancing or strategic financial moves.
• Product-Specific Risks: An Event of Default can be triggered by an injunction or order prohibiting marketing, selling, or manufacturing of Commercial Products if sales of such products accounted for more than 50% of net sales revenue for the most recent four fiscal quarters, and such prohibition continues for more than 60 consecutive days (unless alternative manufacturing is available).
• Product Recall Risk: A product recall or similar event resulting in a Material Adverse Effect or set-offs exceeding $500,000 in aggregate by Account Debtors against outstanding Accounts could trigger an Event of Default.
• General Default Provisions: Standard default clauses apply, including failure to pay, breaches of representations/warranties/covenants, judgments over $250,000, cross-default on other indebtedness over $250,000, dissolution, bankruptcy proceedings, change of control, and invalid liens.

Future Outlook

The company anticipates the commercial launch of EXXUA in the fourth calendar quarter of 2025, expecting it to serve as a major growth catalyst for years to come. The expanded and extended lending agreement provides added working capital flexibility to support this launch.

Management Comments

• "Following the transformational agreement we entered into earlier this month to commercialize EXXUA, which included the closing of a $16.6 million public offering priced at the market and included the full exercise of the overallotment, we have successfully expanded and extended our lending agreement with Eclipse to provide added working capital flexibility as we prepare for the EXXUA launch later this calendar year."
• "With EXXUA expected to serve as a major growth catalyst for us for years to come, it is gratifying to have the support of equity shareholders and lending partners that support the potential ahead of us."

Industry Context

This announcement positions Aytu BioPharma to enter the substantial U.S. prescription Major Depressive Disorder (MDD) market, valued at over $22 billion with more than 340 million antidepressant prescriptions written in 2024. The focus on EXXUA, a first-in-class selective serotonin 5HT1a receptor agonist, addresses a significant unmet need in the MDD market, particularly concerning the unacceptable side effects (like sexual dysfunction) associated with current therapeutics. EXXUA's clinical trial results, showing comparable incidence of sexual side effects to placebo, could provide a competitive advantage in a crowded but underserved market segment. This strategic move aligns with a broader industry trend of developing targeted therapies with improved side effect profiles to enhance patient adherence and outcomes in chronic conditions like MDD.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to benchmark against.
• However, the mention of EXXUA's 'first-in-class' status and its 'comparable to placebo' sexual side effect profile suggests a potential differentiation in the over $22 billion U.S. MDD market, where existing therapies often have significant sexual side effects. This could position EXXUA favorably against established antidepressants like SSRIs and SNRIs, which are known for such side effects, potentially capturing market share from competitors without directly naming them.

Stakeholder Impact

• Shareholders: The expanded debt facilities, coupled with a recent equity offering, provide capital for the EXXUA launch, which management expects to be a 'major growth catalyst,' potentially leading to increased revenue and long-term shareholder value. However, increased debt also adds financial leverage and risk.
• Employees: The funding for the EXXUA launch could lead to job stability and potential growth opportunities within the company as it expands into the MDD market.
• Customers: The successful launch of EXXUA could provide a new treatment option for adults with Major Depressive Disorder, potentially offering a better side effect profile compared to existing therapies.
• Creditors (Eclipse Business Capital LLC): The extended maturity dates and increased loan amounts represent continued commitment and a larger exposure to Aytu BioPharma, with the expectation of regular interest payments and principal repayments. The revised borrowing base and covenants provide a framework for managing risk.

Next Steps

• Commercial launch of EXXUA anticipated in the fourth calendar quarter of 2025.
• Repayment and permanent reduction of the $1.5 million Eclipse Incremental Advance commencing August 1, 2025, with monthly payments of $125,000.
• Continued monthly installments of $154,762.00 for the Term Loan, commencing July 1, 2024, until the Scheduled Maturity Date.

Key Dates

Recommendation

Keywords

Aytu BioPharma, AYTU, SEC filing, 8-K, debt financing, lending agreement, term loan, revolving credit facility, Eclipse Business Capital, EXXUA, major depressive disorder, MDD, pharmaceutical, biopharma, working capital, corporate finance, debt extension, borrowing base, SOFR